Source comparison
Best Hexarelin Dosage Cardiac Protection 2026: Comparison
1–2 mcg/kg daily CD36 receptor activation Moderate anti-apoptotic signaling; 25–30% infarct size reduction in rodent models Minimal GH pulse (1.5–2× baseline) Maintenance cardioprotection without systemic GH effects Best risk-to-benefit ratio for long-term car
This comparison does not assign a generated winner or score.
- 1–2 mcg/kg daily
- CD36 receptor activation
- Moderate anti-apoptotic signaling; 25–30% infarct size reduction in rodent models
- Minimal GH pulse (1.5–2× baseline)
- Maintenance cardioprotection without systemic GH effects
- Best risk-to-benefit ratio for long-term cardiac research protocols
- 2–4 mcg/kg daily
- CD36 + ghrelin receptor synergy
- Robust cardioprotection; 35–42% infarct reduction, improved LVEF in CHF models
- Moderate GH pulse (3–4× baseline)
- Acute cardiac injury models, pre-conditioning protocols, post-MI research
- Current evidence supports this range as optimal for cardiac-specific outcomes
- 4–6 mcg/kg daily
- GHS-R1a dominance with CD36 saturation
- Plateaued cardiac benefit; no additional infarct reduction vs 4 mcg/kg
- Strong GH pulse (5–7× baseline)
- Mixed protocols targeting both GH and cardiac pathways
- Marginal cardiac gains don't justify increased GH-related side effect risk
- >6 mcg/kg daily
- Primarily GHS-R1a (GH secretagogue)
- Diminished cardiac benefit; receptor desensitization possible with chronic use
- Very strong GH pulse (8–12× baseline)
- GH-focused research only (muscle, metabolism)
- Not recommended for cardiac protection. Side effects outweigh benefits